WO2005100547A1 - 抗原パルスして得られた樹状細胞 - Google Patents
抗原パルスして得られた樹状細胞 Download PDFInfo
- Publication number
- WO2005100547A1 WO2005100547A1 PCT/JP2004/013321 JP2004013321W WO2005100547A1 WO 2005100547 A1 WO2005100547 A1 WO 2005100547A1 JP 2004013321 W JP2004013321 W JP 2004013321W WO 2005100547 A1 WO2005100547 A1 WO 2005100547A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vaccine
- rod
- cells
- present
- shaped
- Prior art date
Links
- 102000036639 antigens Human genes 0.000 title claims abstract description 165
- 108091007433 antigens Proteins 0.000 title claims abstract description 165
- 239000000427 antigen Substances 0.000 title claims abstract description 164
- 210000004443 dendritic cell Anatomy 0.000 title abstract description 9
- 229960005486 vaccine Drugs 0.000 claims abstract description 284
- 238000000034 method Methods 0.000 claims abstract description 82
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 80
- 201000010099 disease Diseases 0.000 claims abstract description 49
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 49
- 238000011282 treatment Methods 0.000 claims description 75
- 239000000203 mixture Substances 0.000 claims description 68
- 210000004369 blood Anatomy 0.000 claims description 52
- 239000008280 blood Substances 0.000 claims description 52
- 241000282414 Homo sapiens Species 0.000 claims description 41
- 238000004519 manufacturing process Methods 0.000 claims description 28
- 229940030156 cell vaccine Drugs 0.000 claims description 26
- 230000028993 immune response Effects 0.000 claims description 25
- 239000000654 additive Substances 0.000 claims description 21
- 229960002520 hepatitis vaccine Drugs 0.000 claims description 21
- 230000000996 additive effect Effects 0.000 claims description 16
- 230000006806 disease prevention Effects 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229940021747 therapeutic vaccine Drugs 0.000 claims description 5
- 230000003449 preventive effect Effects 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 3
- 230000002265 prevention Effects 0.000 abstract description 41
- 230000008569 process Effects 0.000 abstract description 4
- 229940029030 dendritic cell vaccine Drugs 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 365
- 210000001744 T-lymphocyte Anatomy 0.000 description 37
- 208000006454 hepatitis Diseases 0.000 description 25
- 241000282412 Homo Species 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 239000000126 substance Substances 0.000 description 21
- 231100000283 hepatitis Toxicity 0.000 description 18
- 241000700605 Viruses Species 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 210000005087 mononuclear cell Anatomy 0.000 description 15
- 206010028980 Neoplasm Diseases 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 12
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000012980 RPMI-1640 medium Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 230000003213 activating effect Effects 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 210000003071 memory t lymphocyte Anatomy 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 229940079322 interferon Drugs 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 241000700721 Hepatitis B virus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 6
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 241000239290 Araneae Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 5
- 229960001627 lamivudine Drugs 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 4
- 238000010876 biochemical test Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000011076 safety test Methods 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 201000008827 tuberculosis Diseases 0.000 description 4
- 241000272517 Anseriformes Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- -1 HB vaccine Proteins 0.000 description 3
- 102000006354 HLA-DR Antigens Human genes 0.000 description 3
- 108010058597 HLA-DR Antigens Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 231100000354 acute hepatitis Toxicity 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000001147 anti-toxic effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000010230 functional analysis Methods 0.000 description 3
- 229960001438 immunostimulant agent Drugs 0.000 description 3
- 239000003022 immunostimulating agent Substances 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000007951 isotonicity adjuster Substances 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000006472 autoimmune response Effects 0.000 description 2
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 2
- 239000011449 brick Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000004700 fetal blood Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229940124724 hepatitis-A vaccine Drugs 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000001806 memory b lymphocyte Anatomy 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 2
- 229940047091 other immunostimulants in atc Drugs 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 229940033663 thimerosal Drugs 0.000 description 2
- 229960002109 tuberculosis vaccine Drugs 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000272875 Ardeidae Species 0.000 description 1
- KWTQSFXGGICVPE-WCCKRBBISA-N Arginine hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CCCN=C(N)N KWTQSFXGGICVPE-WCCKRBBISA-N 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 229940124726 Japanese encephalitis vaccine Drugs 0.000 description 1
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024238 Leptospirosis Diseases 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 241000283923 Marmota monax Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 208000018583 New-onset refractory status epilepticus Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 208000028207 Weil disease Diseases 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- 230000029586 bacterial cell surface binding Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960005004 cholera vaccine Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 238000012844 infrared spectroscopy analysis Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960005337 lysine hydrochloride Drugs 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 229940124735 malaria vaccine Drugs 0.000 description 1
- 229940041323 measles vaccine Drugs 0.000 description 1
- 229940124731 meningococcal vaccine Drugs 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 229940095293 mumps vaccine Drugs 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940066827 pertussis vaccine Drugs 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229940124733 pneumococcal vaccine Drugs 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 229960003131 rubella vaccine Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229940021648 varicella vaccine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- Dendritic cells obtained by antigen pulsing obtained by antigen pulsing
- the present invention relates to a rod-shaped cell that can be used for prevention or treatment of a disease.
- Spider cells are antigen pre-sending cells (APCs) that have the strongest antigen-presenting ability in vivo, and are activated by presenting incorporated antigen epitopes to T cells. Can enhance the immune response.
- APCs antigen pre-sending cells
- the rod-shaped cell vaccine therapy is performed by using a substance extracted from cancer cell force or a cancer-specific antigen to extrude the rod-shaped cells in vitro to enhance the antigen-presenting ability, and the rod-shaped cell vaccine therapy. It is a treatment method that returns to the living body as a vaccine.
- Cancer Cell Strength The extracted substance is generally a mixture of many kinds of substances. Therefore, a rod-shaped cell vaccine pulsed with a substance extracted from cancer cell force is thought to have pulsed the rod-shaped cells by various types of cancer antigens in the cell-extracted substance, and thus induces a strong immune response against cancer. Expected to be. However, in the case of such a Norse with a mixture of many kinds of substances, the antigen presented by the rod-shaped cells cannot be specified. Therefore, it can be used as a therapeutic vaccine for cancer patients, but it cannot be used as a disease prevention vaccine for healthy individuals.
- rod-shaped vaccine prepared in this way is capable of eliciting a strong immune response against a specific antigen, at the present stage, It is allowed to be administered to healthy individuals for disease prevention, etc.
- Hepatitis is inflammation that occurs in the liver and is mainly caused by viruses, alcohol, and drugs. The most common hepatitis is caused by the hepatitis virus. To date, seven types of hepatitis viruses have been found. In addition, in viral hepatitis in Japan, type B and type C account for the majority.
- Hepatitis B patients are distributed worldwide, and it is said that there are 350 million people infected with hepatitis B virus worldwide.
- the number of infected people in China is estimated to be 120 million, and Southeast Asia, which is extremely large, accounts for more than 70% of the number of infected people worldwide.
- Japan it is estimated that there are more than 1 million people infected with hepatitis B virus, and about 10% of those are chronic hepatitis patients.
- treatment aims to reduce the number of viruses and reduce their activity.
- interferon therapy and lamivudine therapy are known.
- Interferon therapy is the first treatment for hepatitis B that was started about 20 years ago. Interferon plays a role in helping the immune system work to suppress virus growth. Interferon therapy can be expected to be effective as the number of viruses decreases. Generally, interferon therapy is effective in treating hepatitis C, which is 1/1000 of the number of viruses. Treatment can only be effective in about 20% of patients. Also for cirrhosis Interferon becomes more effective when migrating. In addition, interferons used for treatment are expensive to develop and make products, and there are many problems such as bringing a huge economic burden of 200 million yen to patients with one course of treatment! ,.
- Lamivudine is originally a drug developed as a therapeutic agent for AIDS, but is known to be effective for the treatment of hepatitis B. Lamivudine has the effect of directly suppressing the synthesis of viral DNA and has the effect of stopping the rapid worsening of hepatitis B. Lamivudine has been reported to be effective in patients with hepatitis B, for whom interferon has not been effective, but is not effective when the virus is not proliferating. Furthermore, there are problems such as the appearance of lamivudine-resistant virus after long-term administration.
- HB vaccine is generally effective.
- HB vaccines are based on the HBs antigen, the surface antigen of hepatitis B virus.
- humans who are effective with the HB vaccine can have anti-HBs antibodies in their bodies.
- Humans who have developed antibodies will not subsequently be infected with hepatitis B, but even if the antibody level drops several years later, once anti-HBs antibodies have been made in the body, they may be free from infection. it is conceivable that.
- the antibody level can be increased again by boosting.
- An object of the present invention is to provide a rod-shaped cell effective for the prevention or treatment of a disease, and particularly to provide a rod-shaped cell that can be suitably used for the prevention or treatment of hepatitis B. The purpose.
- the present invention is a rod cell having an ability to present HBs antigen, obtained by a method comprising a step of pulsing rod cells with HBs antigen.
- the rod-shaped cells having the ability to present HBs antigens obtained by the present invention can activate T cells by presenting HBs antigen epitopes to T cells and enhance immune responses to HBs antigens. . Therefore, according to the present invention, it is possible to provide a rod-shaped cell having the ability to present HBs antigen, which is effective for the prevention or treatment of hepatitis B.
- the method may further include a step of obtaining blood force of the rod-shaped cells. According to this, it is possible to provide a rod-shaped cell having HBs antigen-presenting ability according to the present invention from a blood-derived rod-shaped cell. In addition, when blood is used, rod-shaped cells can be obtained by a relatively simple operation using a conventionally known method or the like.
- the method may further include a step of collecting the blood from an organism.
- the HBs antigen can be an HBs antigen contained in an HB vaccine.
- an HB vaccine for example, in the case of humans, what is actually sold as an HB vaccine is approved and approved for safety and efficacy in humans, including healthy individuals. Therefore, according to the present invention, it is possible to provide rod-shaped cells having the ability to present HBs antigens, which can be used safely and effectively for humans, for example.
- the rod-shaped cells having the ability to present HBs antigens according to the present invention can be used not only for the purpose of treating hepatitis B patients and the like, but also for healthy subjects. Can also be used for the prevention of hepatitis B.
- hepatitis B can be prevented or treated in other organisms by using rod-shaped cells pulsed with an HB vaccine that is safe and effective for that organism. it can.
- the present invention is a method for producing a rod-shaped cell having HBs antigen-presenting ability, comprising a step of pulsing the rod-shaped cell with an HBs antigen. According to this, it is possible to obtain rod-shaped cells having the ability to present HBs antigens, which are effective for the prevention or treatment of hepatitis B.
- the method for producing a rod-shaped cell having HBs antigen-presenting ability according to the present invention can further include a step of obtaining the above-mentioned rod-shaped cell from blood. According to this, it is possible to obtain a rod-shaped cell having the ability to present an HBs antigen according to the present invention from a blood-derived rod-shaped cell. In addition, when blood is used, rod-shaped cells can be obtained by a relatively simple operation using a conventionally known method or the like.
- the method for producing a rod-shaped cell having HBs antigen-presenting ability according to the present invention can further include a step of collecting the blood from an organism.
- the organism may be a human.
- human type B liver It is possible to obtain rod-shaped cells having the ability to present HBs antigen that are effective in preventing or treating inflammation.
- the HBs antigen can be an HBs antigen contained in an HB vaccine.
- a rod-shaped cell having the ability to present an HBs antigen which can be used safely and effectively for an organism, for example, a human including a healthy person, is effective in preventing or treating hepatitis B. be able to.
- a composition comprising rod-shaped cells having HBs antigen-presenting ability
- the present invention is a composition comprising rod cells having the ability to present HBs antigen according to the present invention.
- the rod-shaped cells having the ability to present HBs antigens according to the present invention are used, for example, in a state mixed with another substance, suspended in another substance, or combined with another substance.
- the rod cells having the HBs antigen-presenting ability according to the present invention are suspended in, for example, PBS, physiological saline, RPMI 1640 medium or the like, or the HBs antigen-presenting ability according to the present invention.
- TNF-a TNF-a ;, IL12, HB vaccine, GM-CSF, OK432, and other immunostimulants can be used in the form of dendritic cells.
- the rod-shaped cells having the ability to present HBs antigens according to the present invention are used in a mode suitable for the purpose of use, or the effect of the rod-shaped cells having the ability to present HBs antigens according to the present invention is achieved. It can be used in an enhanced manner.
- composition according to the present invention may further contain an HB vaccine additive.
- the composition may be an experimental reagent or an experimental kit.
- the rod-shaped cells having the ability to present HBs antigen according to the present invention can be used in a mode suitable for research, for example, immune research.
- the composition may be a pharmaceutical composition.
- the rod-shaped cells having the ability to present HBs antigen according to the present invention can be used in a mode suitable for medical treatment, for example, prevention or treatment of hepatitis B.
- the composition may be an immune response active preparation.
- the rod-shaped cells having the ability to present HBs antigen according to the present invention can be used in a dosage form suitable for activating the immune response against HBs antigen.
- the composition may be a cellular vaccine.
- the rod-shaped cells having the ability to present HBs antigens according to the present invention can be directly administered into a living body, and an immune response against HBs antigens can be activated.
- the cellular vaccine may be a vaccine for preventing or treating hepatitis B.
- the rod-shaped cells having the ability to present HBs antigen according to the present invention contained in the cellular vaccine prevent hepatitis B by activating an immune response against the HBs antigen in vivo, or It becomes possible to treat.
- the present invention is a method for preventing or treating hepatitis B using the rod-shaped cells having the ability to present HBs antigen according to the present invention.
- the rod-shaped cells having the ability to present HBs antigens according to the present invention can prevent or treat hepatitis B by activating an immune response against the HBs antigen.
- conventional HB vaccines such as healthy individuals who have been unsuccessful with conventional HB vaccines, those who are struggling with diseases associated with decreased immune ability, those who are taking immunosuppressants, etc.
- a person who has failed to produce an effect can produce an anti-HBs antibody by the method for preventing or treating hepatitis B according to the present invention, and can prevent or treat hepatitis B.
- the present invention can include a step of administering the rod-shaped cells having HBs antigen-presenting ability according to the present invention to an organism.
- the rod-shaped cells having the ability to present an HBs antigen according to the present invention can prevent or treat hepatitis B by activating an immune response against the HBs antigen in vivo.
- the method for preventing or treating hepatitis B according to the present invention is highly effective as compared with the conventional methods for preventing or treating hepatitis B in which an HB vaccine is directly administered in vivo. Is possible.
- the organism may be a human. According to this, it is possible to prevent or treat human type B hepatitis.
- the present invention is an actin-pulsed rod-shaped cell obtained by a method comprising a step of pulsing a rod-shaped cell with a vaccine.
- vaccine pulsed rod cells include a step of pulsing with a vaccine. It means a rod-shaped cell having an antigen-presenting ability obtained by the method described above.
- Vaccine pulsed rod cells obtained by the present invention can activate T cells by presenting antigen epitopes contained in the vaccine to T cells, and can enhance the immune response to the antigen. Therefore, according to the present invention, it is possible to provide vaccine-pulsed rod cells that are effective in preventing or treating diseases.
- the method may further include a step of obtaining blood force of the rod-shaped cells.
- a step of obtaining blood force of the rod-shaped cells it is possible to provide the vaccine pulsed cells according to the present invention from the blood-derived cells. If blood is used, rod-shaped cells can be obtained by a relatively simple operation using a conventionally known method or the like.
- the method may further include a step of collecting the blood from an organism.
- the organism may be a human. According to this, since a human-derived rod cell can be obtained, the vaccine pulse rod cell according to the present invention can be administered to a human. Therefore, according to the present invention, vaccine-pulsed rod cells that are effective for the prevention or treatment of human diseases can be provided.
- the vaccine can be a disease prevention or treatment vaccine. According to this, it is possible to provide vaccine pulse rod-shaped cells presenting antigens related to the above-mentioned diseases contained in these vaccines. Thus, the disease can be prevented or 'treated.
- the vaccine may be a hepatitis vaccine.
- hepatitis vaccines for example, hepatitis A vaccine, hepatitis B vaccine and the like are known.
- hepatitis vaccine pulse rod cells having hepatitis virus antigen-presenting ability that can be used safely and effectively for humans, for example.
- the hepatitis vaccine pulsed cells according to the present invention can be used not only for the purpose of treating hepatitis for hepatitis patients, but also for healthy subjects. It can also be used for the purpose of preventing hepatitis. In addition to humans, other organisms can prevent or treat hepatitis of the organism by using rod-shaped cells pulsed with a safe and effective hepatitis vaccine. .
- the hepatitis vaccine is preferably an HB vaccine containing an HBs antigen.
- vaccine-pulsed rod cells having the ability to present HBs antigen, which can be used safely and effectively in living organisms, for example, humans including healthy individuals, are effective in preventing or treating hepatitis B. Can be provided.
- the present invention is a method for producing vaccine nors rod cells, comprising the step of pulsing rod cells with a vaccine. According to this, it is possible to obtain vaccine pulse rod-shaped cells effective for the prevention or treatment of diseases.
- the method for producing vaccine-pulsed rod cells according to the present invention can further include a step of obtaining the rod-shaped cells from blood. According to this, it is possible to obtain the vaccine pulse rod-shaped cell according to the present invention from the blood-derived rod-shaped cell. If blood is used, rod-shaped cells can be obtained by a relatively simple operation using a conventionally known method or the like.
- the method for producing vaccine-pulsed rod cells according to the present invention can further include a step of collecting the blood from an organism.
- the organism may be a human. According to this, it is possible to obtain vaccine-pulsed rod cells that are effective for the prevention or treatment of human diseases.
- the vaccine can be a disease prevention or treatment vaccine. According to this, it is possible to provide a vaccine pulse-shaped cell effective for the prevention or treatment of the disease.
- the vaccine can be a hepatitis vaccine. According to this, hepatitis vaccine pulse-like cells having the ability to present hepatitis virus antigens, which are effective for the prevention or treatment of hepatitis, can be used safely and effectively in living organisms, for example, humans including healthy individuals. Can be provided.
- the hepatitis vaccine is preferably an HB vaccine containing an HBs antigen.
- vaccine-pulsed rod cells having the ability to present HBs antigen, which can be used safely and effectively in living organisms, for example, humans including healthy individuals, are effective in preventing or treating hepatitis B. Can be provided.
- a composition comprising vaccine pulse rod-shaped cells
- the present invention is a composition comprising vaccine-pulsed rod cells according to the present invention.
- the vaccine pulse rod-shaped cell concerning this invention can be used in the state mixed with the other substance, the state suspended in the other substance, the state combined with the other substance, etc., for example.
- the cells having the HBs antigen-presenting ability according to the present invention are suspended in, for example, PBS, physiological saline, RPMI 1640 medium or the like, or have the HBs antigen-presenting ability according to the present invention.
- TNF-a ;, IL-12, HB vaccine, GM-CSF, OK432, and other immunostimulants can be used in the form of rod-shaped cells. Therefore, according to the present invention, the vaccine pulsed rod cells according to the present invention can be used in a mode suitable for the purpose of use or in a mode for enhancing the effect of the vaccine pulsed rod cells according to the present invention. become.
- composition according to the present invention may further comprise a vaccine additive.
- the composition may be an experimental reagent or an experimental kit.
- the vaccine pulse rod-shaped cell concerning this invention can be used in the aspect suitable for research, for example, immunology research.
- the composition may be a pharmaceutical composition.
- the vaccine pulse rod-shaped cell concerning this invention can be used in the aspect suitable for medical treatment, for example, prevention of a disease, or a treatment.
- the composition may be an immune response active preparation.
- the vaccine pulse rod-shaped cells according to the present invention were allowed to react with the antigen contained in the vaccine.
- the composition may be a cellular vaccine. This makes it possible to directly administer the vaccine pulse rod cells according to the present invention into a living body, and to activate an immune response to an antigen contained in the vaccine.
- the cellular vaccine may be a disease prevention or treatment vaccine.
- the vaccine pulse rod cells according to the present invention contained in the cellular vaccine prevent the disease by activating an immune response against the antigen contained in the vaccine in vivo, or It becomes possible to treat.
- the present invention is a disease prevention or treatment method using the vaccine pulsed rod cells according to the present invention.
- the disease can be prevented or treated by activating the immune response to the antigen contained in the vaccine-like rod-like cell-powered vaccine according to the present invention.
- the disease can be prevented or treated by activating the immune response to the antigen contained in the vaccine-like rod-like cell-powered vaccine according to the present invention.
- healthy individuals who have been unsuccessful with vaccines that have been used to prevent or treat the above diseases, or those who are suffering from diseases associated with decreased immunity, immunosuppression
- a person who has been unable to exert a sufficient effect of a vaccine such as a person who is administering a drug, can produce antibodies by the prevention or treatment method of the disease according to the present invention, thereby preventing the disease. Or it becomes possible to treat.
- the present invention can include a step of administering the vaccine pulse rod-shaped cell according to the present invention to an organism.
- the above-mentioned disease can be prevented or treated by activating the immune response to the antigen contained in the vaccine in vivo in the vaccine pulse rod-like cell force according to the present invention.
- the disease prevention or treatment method according to the present invention can exhibit a higher effect than the conventional disease prevention or treatment methods by directly administering the vaccine into the living body. Is possible.
- the organism may be a human. According to this, it is possible to prevent or treat human diseases.
- FIG. 1 shows anti-HBs antibody values before administration of HB vaccine pulsed rod cells.
- FIG. 2 Diagram showing changes in HLA-DR and CD86 in rod cells by HB vaccine pulse It is.
- FIG. 3 is a graph showing changes in the ability of rod-shaped cells to support juvenile T cells by HB vaccine pulses.
- FIG. 4 is a graph showing the effect of HB vaccine pulsed rod cells on the proliferation ability of HBs memory T cells using HBs memory rod cells.
- FIG. 5 is a graph showing the effect of HB vaccine pulsed rod cells on anti-HBs antibody production ability using HBs memory T cells.
- FIG. 6 Shows the test items of the safety test of HB vaccine pulsed rod cells by blood biochemical test.
- FIG. 8 is a graph showing the results of CRP inspection.
- FIG. 9 is a graph showing the results of PT inspection.
- FIG. 10 is a graph showing the results of a Creatinine test.
- FIG. 11 Shows the results of a safety test on autoimmune reactions using serum biochemical tests.
- FIG. 12 is a graph showing changes in anti-HBs antibody levels by administration of HB vaccine pulsed rod cells.
- FIG. 13 shows changes in anti-HBs antibody levels by administration of HB vaccine pulsed rod cells.
- FIG. 14 Anti-H of HB vaccine non-responder by administration of HB vaccine pulsed rod cells
- the rod-shaped cells having HBs antigen-presenting ability according to the present embodiment can be obtained by a method including a step of norsing the rod-shaped cells with HBs antigen.
- the rod cells having the ability to present HBs antigen according to the present embodiment it is possible to provide rod cells having the ability to present HBs antigen that are effective for the prevention or treatment of hepatitis B.
- “pulse the rod cells with the antigen” means that the rod cells are taken in and decomposed in the rod cells, and the decomposed antigen is used as a peptide. Say to be ready to present.
- the antigen and the rod-shaped cell are allowed to coexist in the presence of an appropriate site force-in or the like. And culture method.
- the method for obtaining a rod-shaped cell is not particularly limited as long as a rod-shaped cell that can take up an antigen and present this antigen is finally obtained, and various methods can be used.
- hemodynamic rod-shaped cells can be obtained. Specifically, for example, using a method known to those skilled in the art, a method of inducing differentiation of a rod-shaped cell from blood containing a precursor cell of a rod-shaped cell, or directly separating a blood-powered rod-shaped cell The method can be used.
- a method derived from bone marrow cells, umbilical cord blood or peripheral blood CD34 positive progenitor cells mainly using GM-CSF and TNF- ⁇ , umbilical cord blood mononuclear cells or peripheral blood mononuclear cells Mainly using GM-CSF and IL4, method using GM-CSF and IFN- ⁇ mainly from peripheral blood mononuclear cells, method of separating directly from peripheral blood mononuclear cells, etc.
- rod-shaped cells can be obtained.
- the method for obtaining these rod-shaped cells can further include a step of collecting blood from an organism as necessary.
- the organism is not particularly limited depending on whether or not there is a possibility of being infected with hepatitis B, but can be, for example, an organism that can be infected with hepatitis B.
- the organisms that can be infected with hepatitis B can include organisms that can naturally infect hepatitis B and organisms that can be artificially infected with hepatitis B.
- examples of organisms that can naturally infect the hepatitis B include artificial infection of the hepatitis B, such as primates such as humans and chimpanzees, ducks such as woodchuck and Pekindak, etc.
- examples of organisms that can be used include squirrels, rats, ducks, geese, herons, vines, mice, and the like.
- the present invention since the number of deaths due to hepatitis C is increasing worldwide, the present invention has a great effect that can be used when the organism is a human being.
- examples of a method for obtaining a rod-shaped cell without using blood include a method for obtaining a rod-shaped cell by inducing differentiation of an ES cell. Specifically, for example, it exists inside the blastocyst. Existing inner cell mass force Established ES cells can be induced into rod-shaped cells by culturing with appropriate feeder cells and site force in.
- a medium for culturing rod cells is used. Induction of differentiation from a precursor cell of a rod cell to a rod cell, survival of the rod cell, and an antigen-induced cell culture.
- RPMI 1640 medium or the like can be used. Also preferred is RPMI 1640 medium.
- site force-in can be used for the induction of rod-shaped cells.
- the site force-in used for the induction of rod cells is not particularly limited as long as it does not inhibit the differentiation into rod cells, the survival of rod cells, the pulse of rod cells by antigens, etc.
- GM-CSF GM-CSF , TNF- ⁇ , IL 4, IFN- ⁇ and the like can be used.
- the aspect of the HBs antigen is not particularly limited as long as it can be finally presented by rod cells, and may be a complete protein antigen or a peptide antigen.
- the HBs antigen according to the present embodiment can be used in a combination with various substances and liquids, for example.
- HBs antigen is introduced into rod cells using a phospholipid bilayer membrane such as ribosome, or HBs antigen is suspended in a buffer solution such as PBS or a medium such as RPMI 1640 medium. Cloudy and can be introduced into rod cells.
- the timing of adding HBs antigen is not particularly limited as long as HBs antigen can be presented by rod cells as a result. For example, it is added after differentiation induction of rod cells. be able to.
- HBs antigen can be added at the time of induction and cultured together.
- the HBs antigen nose time is not particularly limited as long as the HBs antigen can be presented by the rod cells as a result. For example, it can be 8 hours to 24 hours.
- the HBs antigen can be an HBs antigen contained in an HB vaccine.
- a live vaccine is, for example, a vaccine in which viruses and bacteria with weak pathogenicity are inoculated alive.
- Inactive vaccines for example, purify virus particles, bacterial cells, etc. and treat them with heat or drugs such as formalin to eliminate or detoxify the pathogenicity.
- a vaccine made by Toxoid refers to, for example, a product obtained by removing and purifying only a bacterial toxin and detoxifying it by adding formalin without losing immunogenicity.
- the type of HB vaccine in the present embodiment is not limited as long as it contains an HBs antigen.
- HB vaccines that are licensed for human use and sold are: Classified as inactive vaccine.
- an HB vaccine that is an inactivated vaccine for example, a recombinant precipitated hepatitis B vaccine or a precipitated hepatitis B vaccine can be used.
- a recombinant precipitated hepatitis B vaccine for example, a portion corresponding to the HBs antigen of hepatitis B virus DNA is inserted into and expressed in DNA of yeast, animal cells, etc. It is possible to use a vaccine prepared by preparing an HBs antigen and adding an aluminum gel as an immune enhancer. As animal cells, for example, vaccines prepared using CHO cells can be used.
- the precipitated hepatitis B vaccine for example, a vaccine prepared by purifying an HBs antigen produced by animal cells or the like and then preparing an aluminum gel is used.
- an animal cell for example, a vaccine prepared using huGK-14 cells can be used.
- the method for producing a rod-shaped cell having HBs antigen-presenting ability includes a step of pulsing the rod-shaped cell with an HBs antigen. According to this, it is possible to obtain rod-shaped cells having the ability to present HBs antigens, which are effective for the prevention or treatment of hepatitis B.
- the production method may further include a step of obtaining blood force of the rod-shaped cells. According to this, it is possible to obtain a rod-like cell having the ability to present an HBs antigen according to the present invention from a blood-derived rod-like cell. In addition, when blood is used, rod-shaped cells can be obtained by a relatively simple operation using a conventionally known method or the like.
- the production method may further include a step of collecting the blood from a living organism.
- the organism may be a human. According to this, it is possible to obtain rod-shaped cells having the ability to present HBs antigens, which are effective in preventing or treating human hepatitis B.
- the HBs antigen can be an HBs antigen contained in an HB vaccine. According to this, a rod-shaped cell having the ability to present an HBs antigen, which is effective for the prevention or treatment of hepatitis B, which can be used safely and effectively for an organism, for example, a human including a healthy person, is provided. That's right.
- a composition comprising rod cells having the ability to present HBs antigens
- composition according to the present embodiment can include rod-shaped cells having the ability to present HBs antigen according to the present embodiment.
- composition according to the present embodiment may further contain an HB vaccine additive.
- the composition according to the present embodiment further includes HB vaccine-added carotenoid
- the HB vaccine additive power is somewhere in the entire composition according to the present embodiment. Let's say that it is included. That is, the place where the HB vaccine additive is contained is not particularly limited anywhere outside the rod cells in the composition according to the present embodiment, inside or on the cell membrane.
- the vaccine additive in the composition according to the present embodiment, the HBs antigen contained in the HB vaccine was used as the HBs antigen to obtain a rod-shaped cell having the ability to present the HBs antigen according to the present embodiment. Can be determined.
- HB vaccine additives include preservatives, antibiotics, stabilizers, preservatives, immunostimulants, buffers, isotonic agents and the like. Specific examples include thimerosal, potassium aluminum sulfate, sodium hydroxide, sodium chloride salt, acetic acid, sodium acetate, sodium chloride salt, and the like. The HB vaccine additive is not limited to these.
- a known analysis method can be used. Specifically, for example, separation analysis using various chromatographs, quantitative analysis, infrared spectroscopic analysis, nuclear magnetic resonance analysis, mass analysis, structural analysis by elemental analysis, and the like can be mentioned.
- the composition according to the present embodiment can be an experimental reagent or an experimental kit.
- the rod-shaped cells having the ability to present HBs antigens according to the present embodiment can be used in a mode suitable for various studies. Examples of research fields that can be used include immune responses, Examples include studies on signal transduction mechanisms related to immune tolerance and production of cytodynamic force, and studies on immunotherapy using rod cells. It can also be used for the purpose of, for example, research related to the prevention or treatment of hepatitis B, for example, screening of genes, RNA, peptides, proteins, compounds, pharmaceuticals, cytopower, etc.
- composition according to the present embodiment may be a pharmaceutical composition.
- the pharmaceutical composition according to the present embodiment can be used, for example, in an aspect in which it is directly administered in vivo, or in an aspect where it is mixed with other substances or cells in vitro.
- the composition according to the present embodiment can be an immune response active preparation.
- the immune response active pharmaceutical preparation according to the present embodiment can be used, for example, in an aspect where it is directly administered into a living body, or an aspect where it is mixed with other substances or cells in vitro.
- the immune response activation preparation according to the present embodiment and T cells are mixed, and the HBs antigen epitope is presented to the T cells.
- the usage method which activates a T cell by doing is mentioned.
- the T cells can be administered in vivo.
- examples of a mode in which the composition according to the present embodiment is directly administered into a living body include injection and infusion as a cell vaccine.
- the cell vaccine is preferably a preventive or therapeutic vaccine for hepatitis B.
- as a place where the composition according to the present embodiment is directly administered in vivo for example, intravenous administration, intraarterial administration, intrathoracic administration, intraperitoneal administration, subcutaneous administration, intramuscular administration, intramuscular (for example, Intrahepatic) administration, lymph node administration, and the like. Subcutaneous injection is preferred because of the simplicity of administration.
- the prevention or treatment of hepatitis B using the rod-shaped cells having the ability to present HBs antigens is a step of administering rod-shaped cells having the ability to present HBs antigen to an organism.
- the organism include living organisms that can be infected with hepatitis B as described above. You can list things.
- the rejection reaction can be suppressed, the organism from which the rod-shaped cells are derived and the organism to be administered may be the same or different organisms.
- the rod cells according to the present embodiment can be administered into the removed self body, or can be administered into a non-self body that matches the degree to which the histocompatibility antigen can be administered. It is also possible to do this.
- the organism can be a human.
- the origin of the rod-like cell is preferably a rod-like cell derived from a blood donor.
- rod cells derived from the subject person are more preferable.
- the rod-shaped cells having the ability to present HBs antigens according to the present embodiment are used in a mode of being administered directly into a living body, or mixed with T cells in vitro to activate T cells.
- the T cells can be used in such a manner that they are administered in vivo.
- T cells are single cells, once they function, they die and disappear in a short time. Therefore, in order to prevent and treat hepatitis B, it is necessary to administer T cells repeatedly at a high frequency.
- rod cells also act on naive T cells, HBs memory T cells, and B cells and give repeated stimulation, resulting in a long and powerful effect. From the above, it is considered that it is more preferable to use the rod-shaped cells having the ability to present HBs antigens according to the present embodiment in a mode in which they are directly administered in vivo.
- This use example can include the step of administering to the human the rod-shaped cells having the ability to present HBs antigen according to the present embodiment.
- This use case can be applied to the prevention or treatment of hepatitis B.
- this usage example is not limited to the following cases, The usage mode of the rod-shaped cell which concerns on this usage example can be variously changed in the range which does not exceed the summary of this invention.
- non-responders about 10% of healthy people are non-responders (non-responders) It is known that anti-HBs antibodies cannot be produced even when HB vaccine is administered. Because hepatitis B is transmitted via blood, medical professionals and others are considered to have a particularly high need for anti-HBs antibodies, but there are many HB vaccine non-responders in these people.
- these people can produce anti-HBs antibodies by administering to these HB vaccine non-responders the rod cells having the HBs antigen-presenting ability according to the present embodiment. Become. It is said that anti-HBs antibody levels need to be maintained at least 1 OmIUZml to prevent hepatitis B infection.
- the anti-HBs antibody value of the HB vaccine non-responder increased to an average of 30 mIUZml by once administration of the rod-shaped cells having the ability to present HBs antigen according to the present embodiment. It was found that values above lOmlUZml can be maintained for about 3-6 months. Therefore, the present HB vaccine non-responder can produce anti-HBs antibodies by the rod-shaped cells having the ability to present HBs antigens according to the present embodiment, thereby preventing infection with hepatitis B. it can.
- the HB vaccine currently used for the prevention of hepatitis B usually needs to be inoculated three times at regular intervals.
- healthy administration in which not only the HB vaccine non-responder but also the HB vaccine succeeds by administering the rod cells having the HBs antigen-presenting ability according to the present embodiment once. It was proved that the anti-HBs antibody level of responders can be increased. Therefore, the rod-shaped cells having the ability to present HBs antigens according to the present embodiment can be used not only for HB vaccine non-responders but also for HB vaccine responders as a new means of preventing hepatitis B, The number of inoculations and the economic burden may be reduced.
- antiviral agents have been mainly used for the treatment of hepatitis B. But anti-we It is known that mutant viruses with ineffective antiviral agents appear frequently after long-term administration of a lupus agent. As a result, the amount of hepatitis B virus increased again and there was a risk of hate for hepatitis.
- a patient can produce an anti-HBs antibody by administering to the patient the rod-shaped cells having the ability to present HBs antigen according to the present embodiment.
- the anti-HBs antibody of 1OmlUZml or more can be obtained by administering the rod-shaped cells having HBs antigen-presenting ability according to the present embodiment, for example, once every 3 to 6 months. The value is expected to be maintained. From this, it is possible to significantly reduce the administration frequency compared to the use of anti-HBs human immunoglobulin by using the rod-shaped cells having the ability to present HBs antigen according to the present embodiment. The economic burden can be greatly reduced.
- the existing HB vaccine is a preventive vaccine for hepatitis B, and the therapeutic vaccine for hepatitis B has been used only experimentally.
- the HBs antigen-presenting rod-shaped cells produced using the HB vaccine according to the present embodiment can be used only for the prevention of hepatitis B. It was also possible to use it for treatment. This expands the use of HB vaccines that are currently being used and have been confirmed to be safe and effective. In addition, there are new ways of use that enhance the effectiveness of existing HB vaccines. It can be said that it was found. [0120] From the above, the rod-shaped cells having the ability to present HBs antigens according to the present embodiment have a wide range of uses and great advantages.
- the vaccine-pulsed rod cells according to the present embodiment can be obtained by a method including the step of pulsing the rod-shaped cells with a vaccine. According to this, it is possible to provide a vaccine-like rod-shaped cell that is effective in preventing or treating a disease.
- the method may further comprise a step of obtaining rod-like cells with blood power.
- the addition timing of the vaccine is not particularly limited as long as the antigen contained in the vaccine can be presented by the rod cells as a result.
- the vaccine is added after the differentiation of the rod cells is induced. can do. It is also possible to add a vaccine at the time of induction and culture together.
- the pulse time of the vaccine is not particularly limited as long as the antigen contained in the vaccine can be presented by the rod-like cells as a result. For example, the force of 8 hours can be 24 hours.
- Examples of vaccines that can be used in this embodiment include pertussis vaccine, diphtheria toxoid, tetanus toxoid, polio vaccine, measles vaccine, rubella vaccine, Japanese encephalitis vaccine, influenza vaccine, BCG vaccine and other tuberculosis vaccines.
- Mumps vaccine varicella vaccine, hepatitis A vaccine, hepatitis B vaccine, pneumococcal vaccine, yellow fever cucumber, rabies vaccine, cholera vaccine, Weil's disease autumn / darkness mixed vaccine, horseshoe antitoxin, mouse antitoxin, plague vaccine, MMR Vaccine, Salmonella typhoid vaccine, Infnorenza b bacterium-binding vaccine, meningococcal vaccine, dysentery vaccine, malaria vaccine and the like.
- the vaccine which can be used for this Embodiment is not limited to what was illustrated here.
- the vaccine can be a disease prevention or treatment vaccine.
- the vaccine can be a hepatitis vaccine.
- the hepatitis vaccine can be, for example, an HB vaccine containing an HBs antigen.
- the method for producing vaccine-pulsed rod cells according to the present embodiment includes a step of norsing the rod-shaped cells with a vaccine. According to this, octynol-like cells that are effective in preventing or treating diseases can be obtained.
- the production method may further include a step of obtaining blood force of the rod-shaped cells. According to this, it is possible to obtain the vaccine pulse rod-shaped cell according to the present invention from the blood-derived rod-shaped cell. In addition, when blood is used, rod-shaped cells can be obtained by a relatively simple operation using a conventionally known method or the like.
- the production method may further include a step of collecting the blood from a living organism.
- the organism may be a human. According to this, it is possible to obtain vaccine-pulsed rod cells that are effective for the prevention or treatment of human diseases.
- the vaccine may be a disease prevention or treatment vaccine. According to this, it is possible to provide vaccine-pulsed rod cells that are effective for the prevention or treatment of the above-mentioned diseases.
- the vaccine may be a hepatitis vaccine.
- hepatitis vaccine pulsed rod cells having the ability to present hepatitis virus antigens, which are effective for the prevention or treatment of hepatitis, can be used safely and effectively in living organisms, for example, humans including healthy individuals. Can be provided.
- composition comprising vaccine pulse rod-shaped cells
- the composition according to the present embodiment can include the vaccine pulse rod-shaped cells according to the present embodiment.
- composition according to the present embodiment may further contain a vaccine additive.
- the composition according to the present embodiment further includes a vaccine additive
- the vaccine additive power is included anywhere in the entire composition according to the present embodiment. Say you are in a state.
- the place where the vaccine additive is contained is not particularly limited anywhere outside the rod cells in the composition according to the present embodiment, inside or on the cell membrane.
- vaccine additives include preservatives, antibiotics, stabilizers, preservatives, immunostimulants, buffers, isotonic agents, coloring agents, and the like. Specific examples include thimerosal and formalin as preservatives, erythromycin, erythromycin ratatobionate, kanamycin sulfate, and other additives as antibiotics.
- additives include, for example, purified white sugar, L sodium glutamate, gelatin, lactose, glutamic acid glutamate, D sorbitol, human serum albumin, polysorbate 80, glycine, glucose, sodium hydroxide, potassium aluminum sulfate, salt Aluminum, acetic acid, sodium acetate, sodium chloride salt, potassium salt salt, potassium dihydrogen phosphate, sodium hydrogen phosphate, sodium chloride, phenol red, arginine monohydrochloride, disodium phosphate, monopotassium phosphate, L Arginic acid, lysine hydrochloride, etc. can be mentioned. These other additives can be added as stabilizers, preservatives, immunostimulants, buffers, isotonic agents, colorants. The vaccine additive is not limited to these.
- the composition according to the present embodiment can be an experimental reagent or an experimental kit.
- the vaccine pulse rod-shaped cells according to the present embodiment can be used in a mode suitable for various studies.
- Research fields that can be used include, for example, research on the signal transduction mechanism related to the disease and research on immunotherapy using rod cells.
- research related to prevention or treatment of the disease for example, screening of genes, RNA, peptides, proteins, compounds, pharmaceuticals, cytopower, etc. It can also be used for purposes such as printing.
- the composition according to the present embodiment can be an immune response active preparation.
- the immune response active pharmaceutical preparation according to the present embodiment can be used, for example, in an aspect where it is directly administered into a living body, or an aspect where it is mixed with other substances or cells in vitro.
- composition according to the present embodiment is used in vitro, for example, an immune response activation preparation according to the present embodiment and T cells are mixed, and the antigen contained in the vaccine
- An example is a method of activating T cells by presenting epitopes to T cells.
- these T cells can be administered in vivo.
- examples of the mode of directly administering the composition according to the present embodiment into a living body include injection and infusion as a cell vaccine.
- the cell vaccine is preferably a disease prevention or treatment vaccine.
- as a place where the composition according to the present embodiment is directly administered into a living body for example, intravenous administration, intraarterial administration, intrathoracic administration, intraabdominal administration, subcutaneous administration, intramuscular administration, intramuscular ( Administration), lymph node administration and the like. Subcutaneous injection is preferred because of the simplicity of administration.
- the vaccine pulse rod cells according to the present embodiment can be used for prevention or treatment of diseases.
- the vaccine-pulsed rod cells according to the present embodiment can be used in combination with, for example, conventional methods for preventing or treating the disease.
- the prevention or treatment of the disease according to the present embodiment may include a step of administering vaccine pulse rod-shaped cells to an organism.
- the organism include organisms that can be infected with the disease. If the rejection reaction can be suppressed, the organism derived from the rod-shaped cell and the organism to be administered may be the same or different.
- the rod-shaped cells according to the present embodiment can be administered into the taken-out self body, or the non-self body that matches the degree to which the histocompatibility antigen can be administered. It is also possible to administer it internally.
- the organism can be a human.
- the origin of the rod-like cell is preferably a rod-like cell derived from a blood donor.
- rod cells derived from the subject person are more preferable.
- the vaccine pulse rod-shaped cell according to the present embodiment is used in a mode of being directly administered into a living body, or mixed with a T cell in vitro to activate the T cell.
- T cells can be used in a mode of administration in vivo.
- T cells are effector cells, once they function, they die and disappear in a short time. Therefore, in order to prevent and treat diseases, it is necessary to administer T cells repeatedly at a high frequency.
- rod cells also act on naive T cells, memory T cells, and B cells, repeatedly stimulating them, and have a long and powerful effect. From the above, it is considered that it is more preferable to use the vaccine pulse rod-shaped cells according to the present embodiment in a mode in which they are directly administered in vivo.
- This use example can include a step of administering the vaccine pulse rod-shaped cells according to the present embodiment to a human.
- This use example can be applied to the prevention or treatment of diseases.
- this usage example is not limited to the following cases, The usage mode of the rod-shaped cell which concerns on this usage example can be variously changed in the range which does not exceed the summary of this invention.
- the rod-shaped cell vaccine therapy that has been carried out in cancer treatment or the like has been performed by pulsing the rod-shaped cells using a substance that has also extracted cancer cell power.
- the substance from which cellular force is extracted is generally a mixture of many kinds of substances. Therefore, it is considered that the rod-shaped cells pulsed by using the cell extract material were norsted by various kinds of antigens in the cell extract material.
- the somatopoietic cells treated in this way are a group of various types of rod cells that have antigen-presenting ability, including antigens that cannot be identified or that are not related to the disease. It is thought that.
- the rod-shaped cell vaccine produced in this way should be used for the treatment of patients who have already been ill with disease in the field of cancer treatment. Is not permitted to be administered to healthy individuals. Therefore, it cannot be used as a rod-shaped cell vaccine for healthy individuals for disease prevention.
- vaccine-pulsed rod cells in the present embodiment can be prepared by pulsing rod-shaped cells using a vaccine. What is actually sold as a vaccine is one that has been approved and approved for safety and efficacy by humans, including healthy individuals. Therefore, the rod cells pulsated with the vaccine according to the present embodiment can be used as a rod cell vaccine for the treatment of diseases, and as a rod cell vaccine for the prevention of diseases that can only be used for patients. Can also be used by a person.
- tuberculosis for example, the number of patients in Japan decreased steadily after the war, but the rate of decrease slowed from around 1980, and the number of patients increased for three consecutive years since 1997.
- long-term administration of anti-tuberculosis drugs is indispensable for the treatment of tuberculosis, but in order to prevent the possibility that drug-resistant bacteria will be generated, it is necessary to use two or more types of drugs in combination. there were.
- the vaccine pulse rod-shaped cells according to the present embodiment can be used for the treatment of tuberculosis.
- a vaccine cell rod cell obtained by a method including a step of pulsing with a tuberculosis vaccine such as a BCG vaccine can be used as the vaccine pulse rod cell according to the present embodiment. According to this, it is expected that the frequency of occurrence of the drug-resistant bacteria as described above can be lowered, which is considered to be a great advantage in the treatment of tuberculosis. In addition, for other diseases, it is expected that the same effect can be expected by using vaccine-pulsed rod cells for treatment, and it is expected that it will be a great advantage for the treatment of the disease.
- infection is carried out by incorporating a gene encoding the antigen into a plasmid vector or the like, or by incorporating it into a virus vector or the like.
- a method for expressing a target antigen in rod cells is known.
- these genetically engineered rods are used to prevent disease in healthy individuals, even though they may be used to treat patients who are ill. It's forgiven to be forgiven.
- the vaccine pulsed rod cells in the present embodiment can be used as a therapeutic vaccine for diseases to patients, as well as diseases for healthy individuals. It can be used as a preventive vaccine.
- a mode in which the vaccine pulse rod-shaped cells according to the present embodiment are directly administered into a living body, or a mixture of T cells outside a living body to activate the T cells and make these T cells in vivo By using it in the mode of administration, it is possible to produce an antibody against the target antigen even for a healthy person who has not been able to produce an antibody because the vaccine has not been effective so far.
- the vaccine pulse rod-shaped cells according to the present embodiment have a wide range of uses and great advantages.
- the prevention or treatment of diseases using the vaccine pulsed rod cells according to the present embodiment is completely different from the conventional rod cell vaccine therapy.
- adherent cells were separated according to the following procedure. First, the dish was removed from the culture chamber and allowed to stand in a clean bench for 5 minutes. Thereafter, the dish was tilted obliquely, and the culture medium was slowly washed over the entire adherent cells to perform washing, and lymphocytes were removed.
- Adherent cells obtained in (5) were put into a dish, GM-CSF (Peprotec EC) 800UZml, IL 4 (Peprotech EC) ) was cultured for 4 days in 2 ml of RPMI 1640 medium supplemented with 500 UZml and 5% autoserum.
- HB vaccine pulse rod cells The rod-shaped cells obtained in Experimental Example 1 were divided into two. Add HB vaccine (rHB vaccine “Mitsubishi”, manufactured by Mitsubishi Wellpharma) to a final concentration of 2.5-5 ⁇ gZml and incubate for 8-24 hours and pulse with HBs antigen The prepared rod cells were prepared. (Hereinafter, these cells are referred to as “HB vaccine pulse rod cells”.) Cultivation was performed in a dedicated culture room under conditions of 37 ° C., 5% CO concentration, and 75% air. The other rod cell is HB No tin was added and cultured as a negative control.
- HB vaccine pulse rod cells Cultivation was performed in a dedicated culture room under conditions of 37 ° C., 5% CO concentration, and 75% air.
- the other rod cell is HB No tin was added and cultured as a negative control.
- HB vaccine pulsed rod cells were collected from the dish.
- the collected cells were mixed with PBS, centrifuged at 4 ° C and 1500 rpm for 5 minutes, and the supernatant was discarded. By repeating this operation 5 times, the rod cells were thoroughly washed. The resulting rod cells were added to PBS5001. The same operation was performed on the negative control rod-shaped cells.
- Reagents to be used were purchased and used (PBS: Invitrogen, RPMI 1640: -Pro, etc.), and it was confirmed that the reagents were not turbid with the naked eye and a microscope at the time of use. . In addition, by measuring endotoxin in the culture supernatant, it was confirmed that there was no contamination by microorganisms during the culture process.
- HB vaccine pulsed rod cells have a 1.2-fold increase in HLA-DR expression and a 1.6-fold increase in CD86 expression compared to non-pulsed rod cells. Wow. From these results, it was found that the HB vaccine pulsed rod cells were mature.
- Fig. 3 shows the results of evaluation of uptake ability using a ⁇ -ray counter (LS6500: manufactured by Beckman).
- the vertical axis in Fig. 3 shows the thymidine uptake capacity, and the horizontal axis shows the cases (a) and (b) shown in (3) from the left. From these results, it is clear that HB vaccine-pulsed rod cells have an ability to assist the rejuvenation of T cells compared to non-pulsed rod cells compared to T cells that do not match HLA. I found that it was 2 times higher.
- HBs memory T cell 60 ml of blood was collected from each subject (healthy volunteers who had received repeated HB vaccine administration and HB vaccine responders), and Experimental Example 1 (1), Experimental Example 5 T cells were collected using the method of (2). (Hereafter, this T cell is referred to as “HBs memory T cell”.)
- Spider cells were collected from the same subject using the method of Experimental Example 1 and divided into two. One of the rod cells was used as an HB vaccine pulse rod cell using the method of Experimental Example 2, and the other rod cell was not pulsed with an HB vaccine and used as a negative control.
- a blood sample of 60 ml was collected from the subject (healthy volunteer who has been repeatedly administered HB vaccine and HB vaccine responder), and the method of Experimental Example 1 (1) was used. Mononuclear cells were collected.
- FIG. 5 shows the anti-HBs antibody value
- the horizontal axis shows the cases (a), (b), (c), and (d) described in (2) from the left. From this result, it was found that anti-HBs antibody could not be produced when HB vaccine or non-pulsed rod cells were mixed, but anti-HBs antibody was not mixed when HB vaccine pulse rod cells were mixed. It was found that 15-56mIUZml could be produced.
- Serum was collected using the method of Experimental Example 1 (2), and the anti-HBs antibody value was measured by the CLIA method.
- FIGS. 12 and 14 The results are shown in FIGS.
- the horizontal axis in FIGS. 12 and 14 indicates the week since administration, and the vertical axis indicates the anti-HBs antibody value.
- FIG. 13 shows numerical values of the values in the graph of FIG.
- FIG. 14 is a graph showing the transition of anti-HBs antibody levels in subjects who are HB vaccine non-responders. From the results of Figures 12 and 13, it was found that one administration of HB vaccine nors rod cells made it possible to produce two human anti-HBs antibodies for three subjects who were non-responders of the HB vaccine. It was. Anti-HBs antibody levels also increased in two subjects who were HB vaccine responders.
- the anti-HBs antibody value is 1 OmIUZml or more, and therefore, a single administration of HB vaccine pulsed rod cells can produce a sufficient amount of antibody for the prevention or treatment of hepatitis B. It is thought that there is.
- the subject's ability of lOmlUZml or more that was this HB vaccine responder It was proved that anti-HBs antibody levels could be maintained for at least 3 months.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006512091A JP4852702B2 (ja) | 2004-04-06 | 2005-04-05 | 抗原パルスして得られた樹状細胞 |
PCT/JP2005/006679 WO2005097976A1 (ja) | 2004-04-06 | 2005-04-05 | 抗原パルスして得られた樹状細胞 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-112261 | 2004-04-06 | ||
JP2004112261 | 2004-04-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005100547A1 true WO2005100547A1 (ja) | 2005-10-27 |
Family
ID=35067307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/013321 WO2005100547A1 (ja) | 2004-04-06 | 2004-09-13 | 抗原パルスして得られた樹状細胞 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4852702B2 (ja) |
CN (2) | CN1680549A (ja) |
WO (1) | WO2005100547A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109422813A (zh) * | 2017-08-22 | 2019-03-05 | 中国科学院深圳先进技术研究院 | HBs-α317ScFv重组蛋白、其编码序列、表达载体及应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ729408A (en) * | 2014-08-28 | 2021-12-24 | Pci Biotech As | A method of photochemical internalization (pci) utilizing a antigenic molecule, a photosensitizing agent, and a cytokine |
-
2004
- 2004-09-13 WO PCT/JP2004/013321 patent/WO2005100547A1/ja active Application Filing
- 2004-09-14 CN CNA2004100786256A patent/CN1680549A/zh active Pending
-
2005
- 2005-04-05 JP JP2006512091A patent/JP4852702B2/ja active Active
- 2005-04-05 CN CNA2005800119062A patent/CN1973030A/zh active Pending
Non-Patent Citations (6)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109422813A (zh) * | 2017-08-22 | 2019-03-05 | 中国科学院深圳先进技术研究院 | HBs-α317ScFv重组蛋白、其编码序列、表达载体及应用 |
Also Published As
Publication number | Publication date |
---|---|
JP4852702B2 (ja) | 2012-01-11 |
JPWO2005097976A1 (ja) | 2007-08-16 |
CN1973030A (zh) | 2007-05-30 |
CN1680549A (zh) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040228848A1 (en) | Allogeneic cell therapy: mirror effect | |
JP2001520509A (ja) | 自己免疫細胞療法:細胞組成物、方法およびヒト疾患の治療への応用 | |
JP5856025B2 (ja) | 単球またはnk細胞を入手する方法 | |
Yu et al. | Broad influenza-specific CD8+ T-cell responses in humanized mice vaccinated with influenza virus vaccines | |
AU2010202385A1 (en) | Methods for inducing the differentiation of blood monocytes into functional dendritic cells | |
JP2022550132A (ja) | 制御性t細胞を含む組成物ならびにそれを作製および使用する方法 | |
US20170042998A1 (en) | Modulated immunodominance therapy | |
WO2007043630A1 (ja) | 上気道粘膜下に投与されるnkt細胞刺激剤 | |
US11207401B1 (en) | COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19 | |
Ma et al. | Uric acid enhances T cell immune responses to hepatitis B surface antigen-pulsed-dendritic cells in mice | |
JP4852702B2 (ja) | 抗原パルスして得られた樹状細胞 | |
Onji et al. | Dendritic cells in clinics | |
JP5626990B2 (ja) | Th2細胞誘導用組成物およびTh2型疾患の治療組成物、ならびにこれらの利用 | |
JP7397493B2 (ja) | 治療用途のための樹状細胞のin vitro分化および成熟のための方法 | |
JP2024511052A (ja) | 濃縮された制御性t細胞の集団及びその産生方法 | |
WO2005097976A1 (ja) | 抗原パルスして得られた樹状細胞 | |
US11464851B2 (en) | SARS-CoV-2 vaccines | |
WO2024085085A1 (ja) | Nkt細胞を刺激する樹状細胞からなる樹状細胞製剤の製造方法 | |
KR20060040671A (ko) | 단구성 기원의 자기 유래 자가 관용성 유도 세포 및약제학적 제제에 있어서의 이의 용도 | |
US20230372398A1 (en) | Virus specific t-cells and methods of treating and preventing viral infections | |
EP3981425A1 (en) | Sars-cov-2 vaccines | |
Dáňová | The role of the immune system in the immunopathogenesis of autoimmune diseases and the therapeutic modulation of autoimmune reaction by tolerogenic dendritic cells | |
JP2008536511A (ja) | CD8T細胞の活性化方法{MethodForActivatingCD8TCells} | |
WO2018012479A1 (ja) | 樹状細胞集団の調製方法 | |
JP2008538499A (ja) | CD4T細胞の活性化方法{MethodForActivatingCD4TCells} |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |